Mintz Leads For Axoft In $8 Million Seed Round Demonstrating Continued Dedication To Biotech Start-Up Market
Mintz represented Axoft, a neurotechnology company, in its $8 million seed round led by The Engine, a venture firm spun out of MIT that invests in early-stage Tough Tech companies. The fundraising included additional investors Ab Initio Capital, Decent Capital, Safar Partners, Alumni Ventures, AMINO Capital, LiquidMetal VC, AIBasis, Taihill Ventures, Blindspot Ventures and Mintz.
The fundraising will help to finance pre-clinical studies with the FDA and to scale up prototypes of Axoft’s neural implants “as soft as the brain.” The implants are intended to help people who suffer from conditions like cerebral palsy. Axoft was formed in 2021 out of Harvard University and is now based in Cambridge, Massachusetts.
Member Joshua Fox led the Mintz team acting for Axoft on the fundraising.
“This seed round is an important step in Axoft’s goal of helping patients who suffer from neurological disorders. It’s also a great indicator that there continues to be an active fundraising market for biotech start-ups and investors who want to support the next generation of life sciences companies,” said Member Joshua Fox. “We are happy that we have been a part of that community from the beginning.”
Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise thousands of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to large public companies as well as venture capital firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters. Learn more about Mintz’s Life Sciences Practice here.